Results 151 to 160 of about 14,479 (218)

Evaluation of 89Zr-Labeled Anti-PD-L1 Monoclonal Antibodies Using DFO and Novel HOPO Analogues as Chelating Agents for Immuno-PET. [PDF]

open access: yesACS Omega, 2023
Radaram B   +7 more
europepmc   +1 more source

PLA2R‐Positive Membranous Nephropathy and AA Amyloidosis in an Ethiopian Patient With Chronic Hepatitis B: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT The coexistence of primary phospholipase A2 receptor positive membranous nephropathy and AA amyloidosis in a patient with chronic hepatitis B is an exceedingly rare triad presenting a profound diagnostic and therapeutic challenge. A 38‐year‐old Ethiopian man with nephrotic syndrome and chronic hepatitis B had dual pathology on renal biopsy ...
Betelhem Abreham   +4 more
wiley   +1 more source

Tetraspanin-8 as a Tumor-Selective Immuno-PET Target in Hepatocellular Carcinoma. [PDF]

open access: yesJ Nucl Med
Sheehan-Klenk J   +10 more
europepmc   +1 more source

Validation of simplified uptake measures against dynamic Patlak Ki for quantification of lesional 89Zr-Immuno-PET antibody uptake. [PDF]

open access: yesEur J Nucl Med Mol Imaging, 2023
Wijngaarden JE   +10 more
europepmc   +1 more source

The Dentate Gyrus Grows Throughout Life Despite Turnover of Developmentally‐Born Neurons

open access: yesHippocampus, Volume 36, Issue 3, May 2026.
ABSTRACT Adult‐born hippocampal neurons are highly plastic but there remains uncertainty about the magnitude of neurogenesis and its long‐term functional consequences. Theoretical predictions indicate that adult neurogenesis should lead to substantial growth of the dentate gyrus (DG) granule cell population.
Tina Ciric   +4 more
wiley   +1 more source

Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential. [PDF]

open access: yesTheranostics, 2022
Wuensche TE   +13 more
europepmc   +1 more source

Requiring Caution in the Interpretation of Donor‐Derived Cell‐Free DNA Levels During Cancer Treatment in a Kidney Transplant Recipient.: A Case Report

open access: yesIJU Case Reports, Volume 9, Issue 3, May 2026.
ABSTRACT Introduction Donor‐derived cfDNA (dd‐cfDNA) indicates allograft rejection when > 1% of total cfDNA, but tumor‐derived cfDNA can interfere in cancer patients. Case Presentation A 61‐year‐old male kidney transplant recipient with metastatic renal cell carcinoma (RCC) initiated avelumab and axitinib.
Nanaka Katsurayama   +9 more
wiley   +1 more source

Radionuclide Selection Influences Imaging Outcomes in Immuno-PET with a Brain-Penetrating Anti-Amyloid-β Antibody. [PDF]

open access: yesJ Nucl Med
Lopes van den Broek S   +5 more
europepmc   +1 more source

CAR‐T Cells: Current Status, Challenges, and Future Prospects

open access: yesMedComm, Volume 7, Issue 5, May 2026.
This graphical abstract outlines the current status, challenges, and future prospects of CAR‐T cells. The biological basis of CAR‐T cell therapy is the elegant redirection of adaptive immunity. Its initial successes have exposed a landscape of multifaceted challenges.
Aya Sedky Adly   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy